During breast cancer development, increased presence of leukocytes in neoplastic stroma parallels disease progression; however, the functional significance of leukocytes in regulating protumor versus antitumor immunity in the breast remains poorly understood. Utilizing the MMTV-PyMT model of mammary carcinogenesis, we demonstrate that IL-4-expressing CD4 + T lymphocytes indirectly promote invasion and subsequent metastasis of mammary adenocarcinomas by directly regulating the phenotype and effector function of tumor-associated CD11b + Gr1 -F4/80 + macrophages that in turn enhance metastasis through activation of epidermal growth factor receptor signaling in malignant mammary epithelial cells. Together, these data indicate that antitumor acquired immune programs can be usurped in protumor microenvironments and instead promote malignancy by engaging cellular components of the innate immune system functionally involved in regulating epithelial cell behavior.
INTRODUCTION
Clinical and experimental studies have established that chronic infiltration of neoplastic tissue by leukocytes, i.e., chronic inflammation, promotes development and/or progression of various epithelial tumors (de Visser et al., 2006; Mantovani et al., 2008) ; however, the organ-specific cellular and molecular programs that favor protumor, as opposed to antitumor, immunity are incompletely understood. Although some subsets of leukocytes certainly exhibit antitumor activity, including cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells (Dunn et al., 2006) , other leukocytes, most notably mast cells, B cells, dendritic cells, granulocytes, and macrophages, exhibit more bipolar roles, by virtue of their capacity to either hinder or potentiate tumor progression (de Visser et al., 2005; Mantovani et al., 2008) .
Breast cancer development is characterized by significant increases in the presence of both innate and adaptive immune cells, with B cells, T cells, and macrophages representing the most abundant leukocytes present in neoplastic stroma (DeNardo and Coussens, 2007) . Retrospective clinical studies in human breast cancer have revealed that high immunoglobulin (Ig) levels in tumor stoma (and serum) , and increased presence of extra follicular B cells, T regulatory (T reg ) cells, and high ratios of CD4/CD8 or T H 2/T H 1 T lymphocytes in primary tumors or in draining lymph nodes (LNs) correlate with tumor grade, stage, and overall patient survival (Bates et al., 2006; Coronella-Wood and Hersh, 2003; Kohrt et al., 2005) ; thus, some facets of adaptive immunity might indeed be involved in fostering cancer development in the breast.
However, experimental studies have demonstrated that macrophages in primary mammary adenocarcinomas regulate
SIGNIFICANCE
DeNardo and colleagues demonstrate a tumor-promoting role for T H 2-CD4 + T lymphocytes that elicit protumor, as opposed to cytotoxic bioactivities of tumor-associated macrophages and enhancement of prometastatic epidermal growth factor receptor signaling programs in malignant mammary epithelial cells. This work reveals a protumor regulatory program involving components of the acquired and cellular immune systems that effectively collaborate to promote pulmonary metastasis of mammary adenocarcinomas, and identifies cellular targets, namely CD4 + T effector cells and IL-4 for anticancer therapy.
late-stage carcinogenesis by virtue of their proangiogenic properties , as well as foster pulmonary metastasis by providing epidermal growth factor (EGF) to malignant mammary epithelial cells (MECs) and thereby enhancing their invasive (and metastatic) behavior (Pollard, 2004) . Based on these seemingly disparate observations, we sought to determine whether adaptive immunity also fosters malignancy in the breast by regulating the phenotype or effector functions of tumor-associated macrophages (TAMs) and either activating their protumor properties or alternatively by suppressing their antitumor capabilities. To address this, we utilized an aggressive transgenic mouse model of murine mammary adenocarcinoma development (MMTV-PyMT mice) (Guy et al., 1992) where late-stage carcinogenesis and pulmonary metastasis are regulated by colony stimulating factor (CSF)-1 and tissue macrophages (Lin et al., 2001 ). We evaluated MMTV-PyMT mice harboring homozygous null mutations in genes regulating development of specific lymphocyte subtypes and found that CD4 + T cells potentiate pulmonary metastasis of mammary adenocarcinomas indirectly by enhancing aspects of protumor immunity mediated by TAMs. was analyzed in patient samples of normal/hyperplastic breast tissue (n/h; n = 9), ductal carcinoma in situ (DCIS; n = 6), and invasive ductal carcinomas (IC; n = 150) using tissue microarrays. Figure 2G ), and cells expressing PyMT mRNA ( Figure 2H ) in peripheral blood (PB). To verify that the attenuated metastatic phenotype of CD4-deficient/PyMT mice was specifically due to lack of CD4 + T cells, as opposed to a genetic anomaly in homozygous null mice, we depleted 85-day-old PyMT mice of CD4 + T cells for 25 days and again found reduced pulmonary metastasis ( Figure 2I ) and presence of circulating carcinoma cells in PB ( Figure 2G and PyMT/CD4 À/À mice (n = 3/cohort). Isolated cells were lysed and RNAs assessed by qRT-PCR as described above. Representative assays from two independent cohorts each run at least in triplicate are depicted as mean values ± SEM. Asterisk denotes p < 0.05 by Mann-Whitney in all panels.
Cancer Cell Hi IMCs are recruited into mammary carcinomas and regulate pulmonary metastasis in PyMT mice via activation of TGF-bregulated signaling pathways (Yang et al., 2008) . In order to determine whether CD4 + T cells were also regulating the bioactivity of IMCs, we analyzed their cytokine profile in mammary carcinomas of CD4-proficient versus deficient PyMT mice ( Figures 3M-3Q , Figure S2F ) and found significantly elevated expression of factors indicative of an M1 activation state (e.g., TNF-a and Nos2) with parallel reduction in M2-type factors (e.g., Arg-1 and Tgfb). Thus, CD4 + T lymphocytes significantly regulate cytokine and mediator expression in both IMCs and TAMs in mammary adenocarcinomas.
TAM Phenotype in Mammary Carcinomas
Is T reg Independent In vitro, both CD4 + T effector and T reg cells have the capacity to modulate macrophage cytokine expression (Tiemessen et al., 2007) . In order to determine which of these populations were regulating TAM bioactivity in vivo, we immune-depleted CD25 + T regs by treating cohorts of 80-day- Figure 5A ). When invasive pMEC organoids formed, TAMs were typically localized at the ''invasive fronts'' of invading structures ( Figure 5A , panels c-f). In addition, when TAMs were cocultured with pMEC organoids in the presence of T H 2-type cytokines (IL-4 or IL-13), organoid disruption and formation of invasive structures was significantly enhanced ( Figure 5B ) in a TAM and IL-4 dose-dependent manner ( Figures  S6A and S6B) . In contrast, when IL-4 or IL-13 cytokines were added to organoids alone (without TAMs), no significant change in organoid stability or invasive behavior was observed ( Figure 5B ) indicating that cytokine stimulation of pMEC invasion was mediated by TAMs. Analogous results were found utilizing IL-4-activated TAMs to induce pMEC invasion in standard Boyden Chamber migration assays ( Figure S6C ). In contrast, when TAMs were cocultured with pMEC organoids in the presence of M1-type cytokines (IFNg or LPS) or the immunosuppressive cytokine IL-10, the invasive pMEC phenotype was significantly inhibited and instead additional stability of organoids was observed (
Figure 5B Cocultures were also exposed to exogenous recombinant mouse IL-4 (10 ng/ml) and/or an anti-mouse IL-4 neutralizing antibody (0.5 mg/ml; clone OP06) added 12 hr prior to leukocytes.
95-day-old PyMT mice ( Figure S4A ), resulting in a significant enhancement of pMEC invasive organoids in an IL-4 dependent manner ( Figure 5C ). Taken together with data from the in vivo analysis of TAM phenotype, these data indicate that tumor-associated TAMs are alternatively (M2) activated by IL-4-expressing CD4 + T cells, that together induce invasive behavior of MECs, a bioactivity that is not supported by TAMs isolated from CD4 + T-cell-deficient adenocarcinomas, or when TAMs are ''classically'' activated by factors like IFNg or LPS, or engaged in immunosuppressive programs regulated by IL-10.
IL-4 Regulates TAM Phenotype and Pulmonary Metastasis of Mammary Adenocarcinomas
Because the capacity of tumor-associated CD4 + T lymphocytes to regulate TAM phenotype and pMEC invasion was dependent on T H 2-type cytokines, we hypothesized that neutralization of IL-4 or its receptors in vivo would mirror the phenotype of CD4-deficient/PyMT mice and limit pulmonary metastasis. To address this, we generated PyMT mice either harboring a homozygous inactivating mutation in the IL-4 receptor alpha (IL4Ra) gene (FVB/n, N6), or treated PyMT mice with a neutralizing antibody to IL-4. Similar to CD4 + T-cell-deficient/PyMT mice, both cohorts of PyMT/IL4Ra À/À and IL-4-neutralized/PyMT mice exhibited no significant change in primary tumor latency or burden as compared with controls ( Figure 6A and 6B). However, loss of either IL-4 activity or expression of IL4Ra resulted in significantly reduced numbers of metastatic foci in lungs and overall attenuation of total pulmonary metastasis ( Figure 6C) . Moreover, cytokine analysis of TAMs isolated from both PyMT/IL4Ra À/À and IL-4-depleted/PyMT mice revealed increased expression of M1-type factors (IL-6, Nos2, IL-12p35) and reduced expression of M2-type genes (Arg1 and Tgfb) as compared with TAMs from control mice ( Figures  6D and 6E ) and thus phenocopied the characteristics of TAMs isolated from CD4 + T cell-deficient/PyMT mice ( Figure 3 ).
IL-4 Signaling Induces Macrophage EGF mRNA Expression and EGFR-Dependent Invasion and Metastasis
Because elaboration of the invasion MEC phenotype certainly involved activation of intracellular MEC signal transduction programs, we next sought to identify the soluble mediators released by TAMs following their activation by IL-4 or CD4 + T cells. Thus, we assessed expression of several growth factors associated with epithelial cell invasion and found that TAMs isolated from CD4-proficient/PyMT mice exhibited elevated levels of EGF and Tgfb mRNA expression, as compared with TAMs from CD4 + T-cell-deficient/PyMT mice ( Figures 3K and 7A , and data not shown). In addition, TAMs represent the most abundant cellular source of EGF mRNA in mammary carcinomas ( Figure S6E ). To determine whether enhanced EGF mRNA expression by TAMs was directly due to IL-4 exposure, we evaluated EGF mRNA expression of TAMs following brief exposure to IL-4, CSF-1, IL-4 plus CSF-1, as compared with pMEC conditioned medium alone, and found that EGF mRNA expression was significantly enhanced by IL-4, but only in the presence of CSF-1 or pMEC conditioned medium ( Figures 7A and S6D) . To establish whether activation of EGF receptor (EGFR)-mediated signaling was necessary for TAM-induced pMEC invasion, we evaluated effects of EGFR blockade using the 3D coculture assay, and found that IL-4-regulated TAM-dependent pMEC invasion was significantly diminished in the presence of EGFR tyrosine kinase inhibitors ( Figure 7B ). To determine whether this translated to a diminishment in metastasis in vivo, late-stage (day 110) PyMT mice were treated with PD153035 (25 mg/kg) for 5 hr and the presence of circulating malignant cells quantitatively determined. This brief treatment resulted in a significant decrease in the number of circulating carcinoma cells present in PB ( Figure 7C ), similar to observations by Wyckoff et al. (2007) . Taken together, these data indicate that in response to CD4 + T cell-derived IL-4, M2 effector bioactivity is enhanced in TAMs (and IMCs) that in turn activate invasive and metastatic potential of MECs in mammary adenocarcinomas through their production of proinvasive/metastatic factors such as EGF ( Figure 7D ).
DISCUSSION
We revealed a provocative and functional role for CD4 + T effector cells as potentiators of PB dissemination and pulmonary metastasis of mammary adenocarcinomas through their ability to regulate protumor properties of TAMs. Specifically, T H 2-polarized CD4 + T lymphocytes regulate M1 and M2-type TAM bioactivity by their expression of IL-4. M2-TAMs in turn promote invasive behavior of malignant MECs by high-level production of EGF that subsequently activates MEC EGFR signaling programs, an activity essential for entry into PB, dissemination and outgrowth in the lung. These findings indicate that when CD4 + T lymphocytes are present in a T H 2-type tumor microenvironment, they can promote metastasis by regulating the protumor properties of TAMs, as opposed to limiting or eradicating malignant cells by engaging cytotoxic mechanisms. This realization provides rational for development of anticancer therapeutics that neutralize the protumor properties of both adaptive and innate immune cells in the tumor microenvironment, that when delivered in combination with cytotoxic drugs that bolster antitumor immunity, might thereby extend survival of breast cancer patients with advanced disease.
Effector Function of CD4 + T Cells in Solid
Tumors Is Context Dependent Although our studies have revealed that CD4 + T cells potentiate dissemination and metastasis of mammary adenocarcinomas, it is clear that CD4 + T lymphocytes in other contexts exhibit other bioactivities. Schreiber and colleagues demonstrated that CD4 + T cell deficiency in methylcholanthrene-initiated sarcomas enhanced tumor development (Koebel et al., 2007) . By contrast, following two-stage skin carcinogenesis (dimethylbenzanthracene plus tetradecanoylphorbol-acetate), CD4 + T cell deficiency was associated with diminished tumor development (Girardi et al., 2004) . Thus, tumor etiology, in combination with the tumor microenvironment, regulates CD4 + T cell phenotype, and in part determines whether a protumor, as opposed to an antitumor immune program, is favored. In agreement 
Cancer Cell
Immune Regulation of Mammary Cancer Metastasis with the tissue context-dependent nature of CD4 + T cells, in a mouse model of skin and cervical carcinoma development where oncogenes from human papilloma virus type 16 are expressed behind the keratin 14 promoter/enhancer, skin carcinoma formation is modestly attenuated by CD4 + T cell deficiency, whereas cervical carcinoma development is significantly enhanced (Daniel et al., 2005; Daniel et al., 2003) , again demonstrating that immune responses accompanying tumor development are organ dependent as opposed to oncogene dependent, and, based on the neoplastic and immune microenvironment, can engage either pro-or antitumor immune regulatory programs. CD4 + T lymphocytes have been traditionally classified as either tumor suppressive, such as T H 1 effector cells that repress tumor growth by secretion of IFNg (among other soluble mediators) and support of CTL function, or alternatively tumorpromoting cells, including T regs , that foster tumor expansion by suppressing CD8 + CTLs and NK cells (Trzonkowski et al., 2006 ). The interplay between T H 1 and T regs in regulating tumor immunity is likely critical for the etiology of some malignancies, such as sarcomas (Dunn et al., 2006; Koebel et al., 2007) or lung adenocarcinomas (Woo et al., 2002) . In addition to these, a new class of CD4 + T cells expressing IL-17 have been identified (i.e., T H 17 cells) that might also regulate chronic inflammation and promote tumor development when activated in the presence of TGF-b and IL-6, or IL-23 (Dong, 2008) . In our studies, we found that pulmonary metastasis and M2-bioactivity of TAMs was potentiated by CD4 + T effector cells that express high levels of IL-4, IL-13 and IL-10, as compared with expression of IFNg or IL-17 (Figures 3 and 4) , whereas TAM bioactivities were unaffected by immune depletion of CD25 + T reg cells. Moreover, CD4 + T cells exerted these affects independent of the presence or absence of CD8 + T cells, indicating that protumor functionality does not involve suppression of CTL activity. In addition to indirectly potentiating cancer development by regulating protumor properties of myeloid cells, research from several laboratories has revealed that IL-4 and IL-13 regulate tumor growth through activation of IL-4/13 receptors on epithelial cells. In some human breast carcinoma cell lines, particularly those that express the estrogen receptor a, IL-4 and IL-13 inhibit basal and estrogen-induced cell proliferation in vitro and in xenograph models in vivo (Gooch et al., 2002; Nagai and Toi, 2000) . However, in other breast carcinoma cell lines, IL-4 regulates tumor cell survival by conferring resistance to apoptosis (in vitro) that translates to chemoresistance in xenographs (Todaro et al., 2008) . Palucka and colleagues reported that CD4 + T cells directly enhance early tumor development by their production of IL-13 (Aspord et al., 2007) . In contrast to these, we found no change in the latency or development of primary mammary adenocarcinomas due to either CD4 + T cell or IL4Ra deficiency, indicating that in this model system, CD4 + T cells and IL-4 likely do not provide a survival or proliferative advantage directly to neoplastic cells. Moreover, using the ex vivo cell-based assay, we also found no change in MEC proliferation, acinar morphology, or organoid stability when cocultured with CD4 (Kohrt et al., 2005) . More recently, unsupervised expression profiling from breast-cancer-associated stroma revealed a gene signature predictive of good prognostic outcome (>98%, 5 year survival) that was functionally enriched for elements of a T H 1-type immune response, including genes suggestive of CTL and NK cell activity (Finak et al., 2008) . Conversely, high levels of FOXP3 + T reg cells predict diminished relapse-free and overall survival (Bates et al., 2006) . The interpretation based upon these clinical studies is that the type of CD4 + effector T cell response elicited in an emergent breast cancer might in part determine malignant and metastatic potential. Our data provide some clarity to these profiles wherein we report that T H 2-CD4 + T cells promote metastasis, not by altering CTL responses, but instead by enhancing the protumor bioactivities of myeloid cells, and enhancing intracellular signaling cascades (EGF) required for dissemination and metastasis.
Macrophage-Mediated Pro-versus Antitumor Immunity
Macrophages promote metastasis in several contexts, i.e., by supporting tumor-associated angiogenesis, inducing local immunosuppression, or by promoting malignant cell invasion and entry into circulation (Condeelis and Pollard, 2006) ; however, the molecular mechanisms regulating each of these ''hallmark'' protumor TAM properties have yet to be elucidated. Macrophages are implicated in tumor angiogenesis (a prerequisite for metastasis) by virtue of their capacity to express proangiogenic factors including VEGF and matrix metalloproteinase (MMP)-9 (Giraudo et al., 2004) , and by clinical data in human breast cancers demonstrating their presence correlates with increased microvessel density (Uzzan et al., 2004) . Accordingly, tissue macrophage deficiency in PyMT mice leads to reduced angiogenesis, delayed onset of late-stage carcinomas, and greatly diminished pulmonary metastasis . By comparison, loss of CD4 + T lymphocytes, similar to loss of tissue TAMs, results in reduced presence of circulating carcinoma cells and diminished pulmonary metastasis, but did not impact microvessel density, character of angiogenic vasculature, or expression of Vegf-a or MMP-9 by TAMs or IMCs. These distinctions reflect the fact that CD4 + T-cell-derived factors, including IL-4, regulate only some aspects of TAM bioactivity, in particular invasive and metastatic properties of MECs that are EGF dependent; thus, proangiogenic TAMs are likely regulated by other factors such as hypoxia.
TAMs exhibit immunosuppressive activity via their expression of arginase, IL-10, and TGF-b (Mantovani et al., 2007) . Our data demonstrate that CD4 + T cells and IL-4 induce some but not all of their immunosuppressive properties, specifically expression of Arginase-1, TGF-b, and IL-12, but not IL-10, MHCII, or CD86 (Figure 3 and data not shown). Mantovani and colleagues reported that some aspects of TAM-mediated immunosuppression are regulated by intracellular NF-kB signaling (Saccani et al., 2006) . Moreover, Balkwill and colleagues revealed that ovarian-cancer-associated TAMs, due to IL-1R and MyD88, maintain an immunosuppressive M2 phenotype dependent on IKKb (Hagemann et al., 2008) . In vivo, IKKb-deficient TAMs instead exhibit tumor cell cytotoxicity and switch to a classically activated M1 phenotype (e.g., IL-12 high , major histocompatibility complex II high , IL-10 low , Arginase-1 low ) that promotes regression of advanced ovarian carcinomas by induction of TAM tumoricidal activity and activation of IL-12-dependent NK cell recruitment (Hagemann et al., 2008) . These experimental findings imply that reprogramming TAM phenotype and/or altering the immune microenvironment to foster antitumor activity could diminish tumorigenicity and improve clinical outcome.
Mechanisms of TAMs Induced Epithelial Cell Invasion and Metastasis
Reciprocal interactions between TAMs and MECs together regulate mammary carcinogenesis through activation of a paracrine feed-forward loop involving TAM-expressed EGF and epithelial-expressed CSF-1 (Wyckoff et al., 2004) . This paracrine loop is critical for branching morphogenesis (Gouon-Evans et al., 2000) , as well as for breast carcinoma cells exhibiting ''highvelocity'' polarized movement (chemotaxis) along collagen fibers toward blood vessels directed by perivascular macrophages (Wyckoff et al., 2007) . We propose that these heterotypic interactions are further regulated by factors derived from CD4 + T lymphocytes including IL-4, IL-13, and possibly IFNg. Herein, we demonstrated that activation of TAMs by IL-4, in combination with factors derived from malignant MECs such as CSF1, regulate high-level expression of EGF, that in turn stimulates EGFRinduced MEC invasive behavior in vitro and MEC entry into PB and pulmonary metastasis in vivo. As such, a T H 2-rich microenvironment likely collaborates with existing genetic mutations in neoplastic cells, and thereby fosters development of highly invasive tumors in vivo. In addition to EGF, production of TGFb by M2 TAMs, mesenchymal support cells, and IMCs also enhances invasive and metastatic programming of malignant cells (Yang et al., 2008) . Profiling of human breast carcinomas has revealed that a TGF-b-responsive gene signature predicts lung metastasis (Padua et al., 2008) . Similarly, we found that the absence of CD4 + T cells also resulted in decreased Tgfb expression in TAMs (and IMCs) in mammary adenocarcinomas. The prediction based on these data is that the type of CD4 + effector lymphocyte response elicited by the neoplastic microenvironment functionally modulates critical stromal derived factors, such as EGF and TGFb, that collaborate with tumor-cell-intrinsic programs to regulate invasive and metastatic potential.
Summary
Taken together with clinical and experimental studies, our data indicate that CD4 + T effector lymphocytes potentiate mammary adenocarcinoma metastasis by modulating the protumor properties of TAMs that in turn enhance the invasive potential of malignant mammary epithelial cells. Because late-stage immune-depletion of CD4 + T cells or IL-4 resulted in a significant diminution in circulating malignant carcinoma cells and reduced outgrowth of pulmonary metastases, these provocative findings indicate that anticancer therapeutic strategies targeting the effector bioactivity of T cells might hold promise for treating late-stage disease. Although ongoing genetic alterations clearly play a role in regulating the malignant behavior of a neoplastic cell, our study in combination with others revealing dominant roles played by the tumor microenvironment in regulating malignancy, support the long-standing hypothesis (Bissell et al., 1982) that the host response and microenvironment in which a neoplastic cell evolves is as critical to its evolution as the genetic changes occurring within its nucleus.
EXPERIMENTAL PROCEDURES

Animal Husbandry
Mice carrying the PyMT gene under the control of the MMTV promoter in the FVB/ n background were obtained from Dr. Zena Werb (University of California, San Francisco [UCSF], San Francisco, CA) and have been previously described (Guy et al., 1992) . Generation and characterization of FVB/n mice homozygous null (À/À) for RAG-1, CD4 and CD8 have been described previously (de Visser et al., 2005 mice were backcrossed into the FVB/n strain to N15, N5, N14, N7, and N6, respectively, and then intercrossed with PyMT mice to generate breeding colonies of À/À and +/À PyMT/RAG-1, PyMT/JH, PyMT/CD4, PyMT/CD8, PyMT/ CD4/CD8, and PyMT/IL4Ra mice. Immune depleted mice were injected every 5 days intraperitoneally (i.p.) with either anti-CD4 (400 mg, GK1.5), anti-CD25 (400 mg, PC61), anti-IL-4 (1.0 mg, 11B11), or control rat Ig. All mice were maintained within the UCSF Laboratory for Animal Care barrier facility, and all experiments involving animals were approved by the Institutional Animal Care and Use Committee of UCSF.
Primary and Organoid Cell Culture
Primary nMEC and pMEC pools were established by organoid centrifugation as previously described (Pullan and Strueli, 1996) . Briefly, mammary tissue biopsies were harvested from 76-day-old PyMT female or 12-week-old virgin negative littermates and digested with Collagenase A 2.0 mg/ml (Roche) and DNase 2.0 units/ml (Roche) for 2 hr. Organoids were then isolated by differential centrifugation and grown in culture conditions as previously described (Pullan and Strueli, 1996) . Primary nMECs were used within two passages and primary pMEC cells were used within ten passages. Three-dimensional organotypic cultures were established as previously described (Debnath et al., 2003; Lee et al., 2007) . Cultrex basement membrane extract (BME; R&D Systems) was utilized to limit endotoxin levels. Cocultures with primary leukocytes were established only after stable organoid structures had formed (approximately 3 weeks for nMEC, 2 weeks for pMEC). Leukocytes were overlaid in medium containing 0.5% BME. Formation of invasive acini was assessed every 12 hr for 3 days. The cytokines IL-4 (20 ng/ml), IL-13 (20 ng/ ml), IL-10 (10 ng/ml), IFNg (5.0 ng/ml) (Peprotech), or LPS (1.0 mM/ml) were added to cocultures 12 hr after leukocytes overlay. Inhibitors PD153035 (0.1 mM, Calbiochem) or BIBX1382 (10 nM, Calbiochem) were added 1.0 hr prior to the addition of leukocytes. All experiments were repeated two or three times with separate pMEC pools and individual experiments were run at least in triplicate.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism and/or InStat Software. Specific tests used were Student's t test, Mann-Whitney (unpaired, nonparametric, two-tailed), unpaired t test Welch corrected, generalized
Wilcoxon test, and log rank analysis. All p values less than 0.05 were considered statistically significant. Additional experimental procedures are included in Supplemental Experimental Procedures.
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